Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab for RA Inadequately Controlled by Methotrexate
NCT02760407Phase 3Completed
- Sponsor
- R-Pharm
- Start
- Jun 2016
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of olokizumab in rheumatoid arthritis (RA) (4 arms), sponsored by R-Pharm. Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02760407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760407.